logo

Last Update

This profile was last updated on 7/19/2016 and contains contributions from the  Zoominfo Community.

is this you? Claim your profile.

Wrong Donna Bush?

Donna M. Bush

Senior Forensic Toxicologist

Centers for Medicare & Medicaid Services

HQ Phone:  (410) 786-3000

Email: d***@***.gov

GET ZOOMINFO GROW

+ Get 10 Free Contacts a Month

Please agree to the terms and conditions.

I agree to the  Terms of Service and  Privacy Policy. I understand that I will receive a subscription to ZoomInfo Grow at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

THANK YOU FOR DOWNLOADING!

computers
  • 1.Download
    ZoomInfo Grow
    v sign
  • 2.Run Installation
    Wizard
  • 3.Check your inbox to
    Sign in to ZoomInfo Grow

I agree to the Terms of Service and Privacy Policy. I understand that I will receive a subscription to ZoomInfo Community Edition at no charge in exchange for downloading and installing the ZoomInfo Contact Contributor utility which, among other features, involves sharing my business contacts as well as headers and signature blocks from emails that I receive.

Centers for Medicare & Medicaid Services

7500 Security Boulevard

Windsor Mill, Maryland,21244

United States

Company Description

Since 1996 CMS has grown from seven associates to nearly 200 associates today. Our company environment still reflects our humble roots, emphasizing employee cooperation and empowerment. We are dedicated to equipping our staff with the knowledge and tools to ...more

Background Information

Employment History

Senior Forensic Toxicologist

Department of Health


Marketing Manager

Canberra Theatre Centre


Scientific Reviewer

Food and Drug Administration


Affiliations

PharmChem Laboratories , Inc.

Advisory Board Member


Canberra International Music Festival

Board Member


Ausdance SA

Board Member


GroupSpaces Ltd

Board Member


Drug Testing Clearinghouse

Member of Advisory Board


Education

Ph.D.


Web References(50 Total References)


Drug Testing - Drug Testing Advisory Board Meeting 4-30-97

drug-testing.i8.com [cached]

DR. BUSH: Following our instructions, for those
DR. BUSH: Thanks. For the record, I know that DR. BUSH: There is a commercial product so named? DR. BUSH: The names of the devices. Some of the characteristics, descriptions. DR. BUSH: David Evans was the point person on onsite drug testing. Dr. Joseph Autry or Dr. Donna Bush at the Division of Workplace Programs, CSAP, abbreviation for Center for Substance Abuse Prevention, SAMHSA, our parent organization. As you heard, I think it was Donna Bush or Donna Smith this morning that said the government does not move fast, and that is certainly going to be true in this area, just because of the logistics that you have to go through when you have rulemaking.


Contact Us & Meet the Board « Ausdance ACT

ausdanceact.org.au [cached]

MEMBER :: Donna Bush
Commenced on the Board in May 2011. Donna has held senior marketing and communications and corporate affairs roles with Canberra Theatre Centre, Canberra Glassworks, Greening Australia and Royal College of Nursing, Australia. Her love of dance began the moment she found she could twirl in a tutu and consolidated in high school under instruction from Priscilla Ruffel. Her commitment to arts marketing over the past 12 years has included developing and implementing marketing and communications plans for Canberra Theatre Centre, Canberra Glassworks, Tuggeranong Arts Centre and Canberra International Music Festival. In 2004 Donna developed an audience development strategy for Sydney Opera House's House Ed program and in 2009 for Oxfam's Refugee Realities program. Donna is also on the Board of Pro Musica presenters of the Canberra International Music Festival. Her current role is Marketing and


ausdanceact.org.au

MEMBER :: Donna Bush
Donna has held senior marketing and communications and corporate affairs roles with Canberra Theatre Centre, Canberra Glassworks, Greening Australia and Royal College of Nursing, Australia. Her love of dance began the moment she found she could twirl in a tutu and consolidated in high school under instruction from Priscilla Ruffel. Her commitment to arts marketing over the past 12 years has included developing and implementing marketing and communications plans for Canberra Theatre Centre, Canberra Glassworks, Tuggeranong Arts Centre and Canberra International Music Festival. In 2004 Donna developed an audience development strategy for Sydney Opera House's House Ed program and in 2009 for Oxfam's Refugee Realities program. Donna is also on the Board of Pro Musica presenters of the Canberra International Music Festival. Her current role is Marketing and


The Board : Canberra International Music Festival : GroupSpaces

groupspaces.com [cached]

Donna Bush, Board Member
Senior marketing and communications and corporate affairs roles with Canberra Theatre Centre,


Drug Testing - Drug Testing Advisory Board Meeting-3/8-9/99

drug-testing.i8.com [cached]

Dr. Bush (HHS): One of the handouts is titled, an Evaluation of Non-instrumented Drug Test Devices.
There's a background and a summary of the device evaluation itself. This report reviews 15 devices. They are listed by name with the distributor, address, and phone number. The analytical data is presented in both a table and a graph format. Dr. Bush: That is a good point. Dr. Bush: Do we need to go over each one? Dr. Bush: Reflect back to the table as of August 20, 1998. Dr. Bush: When you say, can satisfy the requirement that we as a group could craft statements and craft collection criteria and training requirements? Ms. Bernstein: I want to go back to Dr. Bush's issue - is this something or do we have to make this decision today? Dr. Bush: Any negative comments from the Board members? Dr. Bush: Carl, I think I missed part of that. Dr. Bush: That will be the submission for the analysis? Dr. Bush: No, you only take the 3.9 centimeters that are closest to the head, then you take the rest of this long hair and throw it away. Dr. Bush: Have you seen any data on that like from retests that have been at a later time? So the example earlier of Donna Bush's hair was probably incorrect or misleading. We're talking about a sample about the size of a pencil lead, the lead of a pencil when compressed. Dr. Bush: We will have to tie D together. Dr. Bush: More discussion is needed so we will leave it as an I now. Dr. Bush: That changes from a P to a blank. Dr. Bush: We will deal with that later. Dr. Bush: So that becomes a blank? Dr. Bush: If we establish the requirement, then I assure you the kits will be manufactured and precision shall follow. Dr. Bush: Yes, tie it to D. It will be an easy evaluation next time if it is tied. Dr. Bush: Do we just leave it as P and move on? Dr. Bush: It's already a blank, but there is still more needed discussion. COL Jacobs: In other words we can satisfy the requirements, but we haven't decided what the requirements are? Dr. Bush: Exactly, how to do to that, to establish the cutoffs. Okay, fine. Dr. Bush: Which one are we on? Page 22? Dr. Bush: This is just confirmatory. Dr. Bush: This may be where studies are developed for presentation next time. Dr. Bush: What's going on with Florida? Dr. Bush: I've never been told about how to do it or how the specimens are collected. Dr. Bush: My concern is whether we get reference laboratories and reference values for this. Dr. Bush: We will leave that for now? COL Jacobs: That's correct. Dr. Bush: Let's leave it until we get additional information. Dr. Bush: Do we want to link that back to the cutoffs and the analytes? COL Jacobs: Are we on page 30? Dr. Bush: Yes, Page 30. Dr. Bush: But that may change based upon how we change the cutoffs. Dr. Bush: Yes, but we are unclear as to analyte concentrations and are you going to revisit that? Dr. Bush: Agree, it shouldn't be any different. Dr. Bush: 4-a on Page 34? Dr. Bush: In the current program as it exists? Dr. Bush: My understanding is that passive exposure has not been an issue that has been raised in DOT. Dr. Bush: Element 4 on Page 34 outlines that passive exposure may contribute to a hair positive, may be responsible for a positive hair test. Dr. Bush: Once we get that information from all the incompletes. Dr. Bush: Was this concept to aid in the evaluation of information presented by the donor to the MRO? Dr. Bush: Let's consider it something like a detection window in an oral fluid. Dr. Bush: It is a detection window, establishing the detection window. But today we have chosen to start today looking at one of the other technologies, and I'm going to have Dr. Bush introduce you to that group and to the process. Dr. Bush: As follow-up to what Bob was saying, in our September meeting, we had some formal presentations by the industry representatives from the Working Group. As Donna had said, there has not been any discussion since we met in September pursuant to responding to the issues and questions that were asked of the industry back then. Dr. Bush: They have made it clear that they are open to our discussions and will entertain any recommendations that the Board makes. Dr. Bush: A question concerning retest? Dr. Bush: Alternatively, one could consider that initial eluate, the original specimen, then take an aliquot from that for screening, an aliquot from that for confirmation. Dr. Bush: That applies to any oral fluid collection device where you would have a pad where you perform an initial extract which then becomes the volume from which aliquots may be taken, so point well taken. Dr. Bush: I suggest that Board members take a look at the pros and cons and evidentiary requirements. Dr. Bush: This is E-6? Dr. Bush: Are you looking to get quantification so you can compare that sample? I would be looking for regular retest type of scenario. Dr. Bush: So I'm hearing that it's a fact that certain kits have been cleared for testing the patch. It's a fact that it is cleared? Dr. Bush: That's where I was going. The test kit should be cleared by the FDA as a diagnostic medical device. Dr. Bush: It goes back to your original concept of what is the original specimen, the eluate or the patch? Dr. Bush: Can I clarify something here? Dr. Bush: That's consistent. Dr. Bush: And the marrying of the screen and the confirmed method for the analyte. Dr. Bush: Excuse me for backing up a minute here, but if we go back to Page 18, G-5a. Dr. Bush: I would like to ask a question just concerning that matrix itself. Dr. Bush: That will take some of that matrix effect -- it is like a blank urine. Dr. Sample: In my mind, it is like spiking a blank urine. Dr. Bush: You have a big pool of negative blank urine and then adding the analytes of interest, and using that, then packaging it and then sending it. Dr. Bush: We've had immunoassay manufacturers make our performance in the urine testing program a little more difficult too. Dr. Bush: Yes. Dr. Bush: Were there any females included in those studies that were done? Dr. Bush: Did you capture that information, what the sweat patch result was, and the identity of the person to that type of demographic? Dr. Bush: I think it may be a good idea if you go back through your database and gather that information. Dr. Bush: It would be good if you could isolate that by dose, by drug, and the other demographics. Dr. Bush: I understand. Dr. Bush: If we could supply you with some administrative support, could you do that? Dr. Bush: You're right, Denny.


Similar Profiles

city

Browse ZoomInfo's Business
Contact Directory by City

city

Browse ZoomInfo's
Business People Directory

city

Browse ZoomInfo's
Advanced Company Directory